Anemia and myocardial ischemia: Relationships and interferences;Anemia ed ischemia miocardica: Relazioni ed interferenze

Recenti Progressi in Medicina

Volumn 97, Issue 3, 2006, Pages 153-164

  Bellotto, Fabio ^a,b   Cati, Arianna ^a  

^a Clinica Cardiologica   (Italy)

^b Clinica Cardiologica   (Italy)

Author keywords

Anemia; Cardiac troponin; Coronary disease; Hemoglobin; Ischemia

Indexed keywords

HEMOGLOBIN; TROPONIN;

ACUTE DISEASE; ANEMIA; ARTERIAL PRESSURE; ATHEROSCLEROSIS; CARDIAC PATIENT; CHRONIC DISEASE; DIASTOLE; DISEASE EXACERBATION; HEART MUSCLE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE NECROSIS; HEART OUTPUT; HEART RATE; HEART VENTRICLE CONTRACTILITY; HEART VENTRICLE VOLUME; HEMATOCRIT; HUMAN; OXYGEN CONSUMPTION; OXYGEN SUPPLY; OXYGEN TRANSPORT; REVIEW; RISK FACTOR; TACHYCARDIA;

ANEMIA; CARDIOVASCULAR DISEASES; HUMANS; MYOCARDIAL ISCHEMIA; RISK FACTORS;

EID: 33645977802     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Davies SW. Clinical presentation and diagnosis of coronary artery disease: stable angina. British Medical Bullettin 2001; 59: 17-27.
2. Wang H, Lawrence JL, Richman CM, Wun T. Acute myocardial infarction in hemoglobin SC disease. Ann Hematol 2004; 83: 622-24.
3. Dhawan S, Tak T. Myocardial infarction in a patient with thrombotic thrombocytopenic purpura. Int J Cardiol 2004; 95: 339-41.
4. Fridlender ZG, Rund D. Myocardial infarction in a patient with β-thalassemia major: first report. Am J Hematol 204; 75: 52-55.
5. Vasica G, Tennant CC. Cocaine use and cardiovascular complications. Med J Aust 2002; 177: 260-62.
6. Benzaquen BS, Cohen V, Eisenberg MJ. Effects of cocaine on the coronary arteries. Am Heart J 2001; 142: 402-10.
7. World Health Organization, Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser 1968; 405: 3-37.
8. Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant 2000; 15 suppl 3: 14-18.
9. Neill WA, Oxendine JM, Moore SC. Acute and chronic cardiovascular adjustments to induced anemia in dogs. Am J Physiol 1969; 217: 710-4.
10. Oski FA, Marshall BE, Cohen PJ, Sugerman HJ, Miller LD. Exercise with anemia: the role of left and right shifted oxygen-hemoglobin equilibrium curve. Ann Int Med 1971; 74: 44-6.
11. Varat MA, Adolph RJ, Fowler NO. Cardiovascular effects of anemia. AM Heart J 1972; 83: 415-26.
12. Eckardt KU. Anemia in end-stage renal disease: pathophysiological considerations. Nephrol Dial Transplant 2001; 16 Suppl 7: 2-8.
13. th ed. Philadelphia: Saunders 2001.
14. Beard JL, Tobin BW, Smith SM. Effects of iron repletion and correction of anemia on norepinephrine turnover and thyroid metabolism in iron deficiency. Proc Soc Exp Biol Med 1990; 193: 306-12.
15. Muller R, Steffen HM, Brunner R, Saric J, Pollok M, Baldamus CA, et al. Changes in alpha adrenergic system and increase in blood pressure with recombinant human erythropoietin (rHuEpo) therapy for renal anemia. Clin Invest Med 1991; 14: 614-22.
16. Martin C, Yu AY, Jiang BH, Davis L, Kimberly D, Hohimer AR, et al. Cardiac hypertrophy in chronically anemic fetal sheep: increased vascularization is associated with increased myocardial expression of vascular endothelial growth factor and hypoxia-inducible factor 1. Am J Obst Gynecol 1998; 178: 527-34.
17. Davis LE, Hohimer AR, Morton MJ. Myocardial blood flow and coronary reserve in chronically anemic fetal lambs. Am J Physiol 1999; 277(1 Pt 2): R306-13.
18. Ziehe M, Parenti A, Ledda F, Dell'Era P, Granger HJ, Maggi CA, et al. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res 1997; 80: 845-52.
19. Rakusan K, Cicutti N, Kolar F. Effect of anemia on cardiac function, microvascular structure, and capillary hematocrit in rat hearts. Am J Physiol Heart Circ Physiol 2001; 280: H1407-14.
20. Hudlicka O, Brown M, and Egginton S. Angiogenesis in skeletal cardiac muscle. Physiol Rev 1992; 72: 369-417.
21. Opie LH. Ventricula function. In: Rosendorff C (ed). Essential cardiology. Philadelphia: Saunders 2001.
22. Weiskopf RB, Viele MK, Feiner J, Kelley S, Liberman J, Noorani M, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA 1998; 279: 217-21.
23. von Restorff W, Höfling B, Holtz J, Bassenge E. Effects of increased blood fluidity through hemodiluition on coronary circulation at rest and during exercise in dogs. Pflügers Arch 1975; 357: 15-24.
24. Guyton RA, McClenathan JH, Michaelis LL. Evolution of regional ischemia distal to a proximal coronary stenosis: self-propagation of ischemia. Am J Cardiol 1977; 40: 381-92.
25. Johnson PC. Autoregulation of blood flow. Circ Res 1986; 59: 483-95.
26. Marcus ML. The coronary circulation in health and disease. New York: McGraw-Hill 1983.
27. Reis SE, Holubkoy R, Conrad Smith AJ, Kelsey SF, Sharaf BL, Reichek N, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J 2001; 141: 735-41.
28. Bhatti N, Amoateng-Adjepongg Y, Qamar A, Manthous CA. Myocardial infarction in critically ill patients presenting with gastrointestinal hemorrhage: retrospective analysis of risks and outcomes. Chest 1998; 114: 1137-42.
29. Emenike E, Srivastava S, Amoateng-Adjepongg Y, al-Kharrat T, Zarich S, Manthous CA. Myocardial infarction complicating gastrointestinal hemorrhage. Mayo Clin Proc 1999; 74: 235-41.
30. Prendergast HM, Sloan EP, Cumpston K, Schlichting AB. Myocardial infarction and cardiac complications in emergency department patients admitted to the intensive care unit with gastrointestinal hemorrhage. J Emerg Med 2005; 28: 19-25.
31. Cappell MS. A study of the syndrome of simultaneous acute upper gastrointestinal bleeding and myocardial infarction in 36 patients. Am J Gastroenterol 1995; 90: 1444-49.
32. Layland M, Mythen MG, Wang KY, Albaladejo P, Leone BJ. Measurement of gastrointestinal intramucosal pH is a poor guide to tolerable levels of anemia during isovolemic hemodilution in a canine model of coronary stenosis. Arch Surg 1997; 132: 547-52.
33. Bellotto F, Fagiuoli S, Plebani M, Silverj E, Pavei A, Zaninotto M, et al. Anemia and ischemia: myocardial injury in patients with gastrointestinal bleeding. Am J Med 2005; 118: 548-51.
34. Sarnak MJ, Tighiouart H, Manjunath G, MacLeod B, Griffith J, Salem D, et al. Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) Study. J Am Coll Cardiol 2002; 40(1): 27-33.
35. ARIC Investigators: The Atherosclerosis Risk In Communities (ARIC) study: design and objectivies. Am J Epidemiol 1989; 129: 687-72.
36. Arant CB, Wessel TR, Olson MB, Bairey Merz CN, Sopko G, Rogers WJ, et al. Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain. Results from the National Heart, Lung, and Blood Institute Women's Ischemia Syndrome Evaluation Study. J Am Coll Cardiol 2004; 43: 2009-14
37. JD Hosenpud, et al. Other causes and contributing factors to congestive HF. In: Congestive HF. New York-Berlin: Springer Verlag 1994: 281-300
38. Parfrey PS, Harnett JD, Barre PE. The natural history of myocardial disease in dialysis patients. J Am Soc Nephrol 1991; 2: 2-12.
39. London GM, Parfrey PS. Cardiac disease in chronic uremia: pathogenesis. Adv Ren Replace Ther 1997; 4: 194-211.
40. Lester LA, Sodt PC, Hutcheon N, Arcilla RA. Cardiac abnormalities in children with sickle cell anemia. Chest 1990; 98: 1169-74.
41. Grossman W. Cardiac hypertrophy: useful adaptation or pathological process? Am J Med 1980; 69: 576-84.
42. Hegarty J, Foley RN. Anemia, renal insufficiency and cardiovascular outcome. Nephrol Dial Transplant. 2001; 16 suppl 1: 102-4.
43. O'Riordan E, Foley RN. Effects of anemia on cardiovascular status. Nephrol Dial Transplant 2000; 15 Suppl 3: 19-22.
44. London GM, Marchais SJ, Guerin AP, Fabiani F, Metivier F. Cardiovascular function in hemodialysis patients. Adv Nephrol Necker Hosp 1991; 20: 249-73.
45. Mann JFE. What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol Dial Transplant 1999; 14: 29-36.
46. London GM, Drüeke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51: 1678-95.
47. London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996; 50: 600-8.
48. Barenbrock M, Spieker C, Laske V, Rahn KH. Studies of the vessel wall properties in hemodialysis patients. Kidney Int 1994; 45: 1397-1400.
49. Kawagishi T, Nishizawa Y, Konishi T, Kawasaki K, Emoto M, Shoji T, et al. High-resolution B-mode ultrasonography in evaluation of atheroslerosis in uremia. Kidney Int 1995; 48: 820-6.
50. Amann K, Wiest G, Neusüß R, Ritz E, Irzyniec T, Wiest G, et al. Changes of vascular architecture independent of blood pressure in experimental uremia. Am J Hypertens 1995; 8: 409-17.
51. Joosten E, Pelemans W, Hiele M, Noyen J, Verhaeghe R, Boogaerts MA. Prevalence and causes of anemia in a geriatric hospitalized population. Gerontology 1992; 38: 111-7.
52. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
53. Zoccali C, Mallamaci F, Tripepi G. Inflammation and atherosclerosis in end-stage renal disease. Blood Purif 2003; 21: 29-36.
54. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-11.
55. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855-60.
56. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
57. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-Reactive Protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.
58. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, et al. C-Reactive Protein in heart failure: prognostic value and the effect of Valsartan. Circulation 2005; 112: 1428-34.
59. Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. J Am Coll Cardiol 2005; 45: 637-51.
60. Sherwood A, Hinderliter AL, Watkins LL, Waugh RA, Blumenthal JA. Impaired endothelial function in coronary heart disease patients with depressive symptomatology. J Am Coll Cardiol. 2005; 46: 656-9.
61. Barasch E, Kaushik V, Gupta R, Ronen P, Hartwell B. Elevated cardiac troponin levels do not predict adverse outcomes hospitalized patients without clinical manifestations of acute coronary syndromes. Cardiology 2000; 93: 1-6.
62. Guest TM, Ramnathan AV, Tuteur PG, Schechtman KB, Ladenson JH, Jaffe AS. Myocardial injury in critically ill patiens. A frequently unrecognized complication. JAMA 1995; 273: 1945-9.
63. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001; 345: 1230-6.
64. Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993; 54: 84-89.
65. Meade TW, Roderick PJ, Brennan PJ, Wilkes HC, Kelleher CC. Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb Haemost 1992; 68: 1-6.
66. Bar-Dayan Y, Amital H, Levy Y, Shoenfeld Y. Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction. Isr J Med Sci. 1996; 32: 288-91.
67. Sorlie PD, Garcia-Palmieri MR, Costas R Jr, Havlik RJ. Hematocrit and risk of coronary heart disease: the Puerto Rico Health Program. Heart J 1981; 101: 456-61.
68. Brown DW, Giles WH, Croft JB. Hematocrit and risk of coronary heart disease. Am Heart J 2001; 142: 657-63.
69. Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease. The Framingham Study: a 34-year follow-up. Am Heart J 1994; 127: 674-82.
70. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005; 111: 2042-9.
71. Zeidman A, Fradin Z, Blecher A, Oster HS, Avrahami Y, Mittelman M. Anemia as risk factor for ischemic heart disease. Isr Med Assoc J 2004; 6: 16-8.
72. Lipsic E, van der Horst IC, Voors AA, van der Meer P, Nijsten MW, van Gilst WH et al. Hemoglobin levels and 30-day mortality in patients after myocardial infarction. Int J Cardiol 2005; 100: 289-92.
73. Thomas MC, MacIsaac RJ, Tsalamandris C, Molyneaux L, Goubina I, Fulcher G, et al. Anemia in patients with type 1 diabetes. J Clin Endocrinol Metab 2004; 89: 4359-63.
74. Vaitkus PT Current status of prevention, diagnosis, and management of coronary artery disease in patients with kidney failure. Am Heart J 2000; 139: 1000-8. Review.
75. USRDS 1995 annual data report, VI. Causes of death. Am J Kidney Dis 1995; 26: S85-94.
76. London GM, Marchais SJ, Guerin AP, Fagiani F, Metivier F. Cardiovascular function in hemodialysis patients. In: Grunfeld JP, Bach JF, Funck-Brentano JL, Maxwell MH, eds. Advances in nephrology. St Louis: Mosby Year Book 1991: vol 20.
77. NFK-DOQITM Work Group. NFK-DOQITM clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997; 30 [suppl 13]: S192-S240.
78. McKechnie RS, Smith D, Montoye C, Kline-Rogers E, O'Donnell MJ, DeFranco AC, et al. Prognostic implication of anemia on in-hospital outcomes after percutaneous coronary intervention. Circulation 2004; 110(3): 271-7.
79. Lee PC, Kini AS, Ahsan C, Fisher E, Sharma SK. Anemia is an independent predictor of mortality after percutaneous coronary intervention. J Am Coll Cardiol. 2004; 44: 541-6.
80. Nelson AH, Fleisher LA, Rosenbaum SH. Relationship between postoperative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit. Crit Care Med 1993; 21: 860-6.
81. Zindrou D, Taylor KM, Bagger JP. Preoperative haemoglobin concentration and mortality rate after coronary artery bypass surgery. Lancet 2002; 359: 1747-8.
82. Hahn RG. Acute myocardial infarction after transurethral resection of the prostate. Biomed Pharmacother. 2001; 55: 144-7.
83. Katzel LI, Sorkin JD, Colman E, Goldberg AP, Busby-Whitehead MJ, Lakatta LE, et al. Risk factors for exercise-induced silent myocardial ischemia in healthy volunteers. Am J Cardiol 1994; 74(9): 869-74.
84. Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 2004; 27: 1954-61.
85. Erratum in: Diabetes Care 2005; 28: 504.
86. Douglas PS, Ginsburg GS. The evaluation of chest pain in women. N Engl J Med 1996; 334: 1311-5.
87. Bellotto F, De Simone G, Dalla Volta S. L'esofago come causa di dolore toracico in pazienti con e senza malattia coronarica. G Ital Cardiol 1995; 25: 489-500.
88. Nair D, Shlipak MG, Angeja B, Liu HH, Schiller NB, Whooley MA. Association of anemia with diastolic dysfunction among patients with coronary artery disease in the heart. Am J Cardiol 2005; 95: 332-336.
89. Colleran JA, Papademetriou V, Narayan P, Lu D, Flechter RD: Electrocardiographic abnormalities suggestive of myocardial ischemia durino upper gastrointestinal bleeding. Am J Cardiol 1995; 75: 312-4.
90. Leung JM, Weiskopf Rb, Feiner J, Hopf HW, Kelley S, Viele M, et al. Electrocardiographic ST-segment changes during acute, severe isovolemic hemodilution in humans. Anesthesiology 2000; 93: 1004-10.
91. Gumming G, Dufresne C, Samm J. Exercise ECG changes in normal women. CMAJ 1973; 109: 108-11.
92. Froelicher V, Thompson A, Longo M Jr, Triebwasser J, Lancaster M. Value of exercise testing for screening asymptomatic men for latent coronary artery disease. Prog Cardiovas Dis 1976; 18: 265-76.
93. Joint European Society of Cardiology, American College of Cardiology Committee. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-69
94. Wu AHB, Ford L. Release of cardiac troponin in acute coronary syndromes: ischemia or necrosis? Clin Chim Acta 1999; 284: 161-74.
95. Ammann P, Maggiorini M, Bertel O, Hanseler E, Joller-Jemelka H, Oechslin E, et al. Troponin as a risk factor for mortality in critacally ill patients without acute coronary syndromes. J Am Coll Cardiol 2003; 41: 2004-9.
96. Bhagavan NV, Goldstein AP, Honda SAA, Uyehara J, Blaisdell J, Sugiyama C, et al. Role of cardiac troponin I in the evaluation of myocardial injury. J Clin Lab Anal 1998; 12: 276-79.
97. Apple FS, Sharkey SW, Hoeft P, Skeate R, Voss E, Dahlmeier BA, et al. Prognostic value of serum cardiac Troponin I and T in chronic dialysis patients: a one-year outcomes analysis. Am J Kidney Dis 1997; 29: 399-403.
98. Cannon CP, Turpie AGG. Unstable angina and non ST-elevation myocardial infarction. Initial antithrombotic therapy and early invasive strategy. Circulation 2003; 107: 2640-45.
99. Collinson PO, Hadcocks L, Foo Y, Rosalki SB, Stubbs PJ, Morgan SH, et al. Cardiac troponins in patients with renal dysfunction. Ann clin Biochem 1998; 35: 380-6.
100. Thiru Y, Pathan N, Bignall S, Habibi P, Levin M. A myocardial cytotoxic process is involved in the cardiac dysfunction of meningococcal septic shock. Crit Care Med 2000; 28: 2979-83.
101. ver Elst KM, Spapen HD, Nguyen DN, Garbar C, Huyghens LP, Gorus FK. Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem 2000; 46: 650-7.
102. Bakshi TK, Choo MKF, Edwards CC, Scott AG, Hart HH, Armstrong GP. Causes of elevated troponin I with normal coronary angiogram. Intern Med J 2002; 32: 520-5.
103. Guerrero-Peral AB, Guerrero-Peral AL, Carrascal Y, Bustamante R, Rodriguez MA, Ponce-Villares MA, et al. Specific markers of myocardial injury in acute stroke. Rev Neurol 2002; 35: 901-4.
104. Pateron D, Beyne P, Laperche T, Logeard D, Lefilliatre P, Sogni P, et al. Elevated circulating cardiac Troponin I in patients with cirrhosis. Hepatology 1999; 29: 640-3.
105. Giannitsis E, Müller-Bardorff M, Kurowsky V, Weidtmann B, Wiegand U, Kampmann M, et al. Independent prognostic value of cardiac Troponin T in patiens with confirmed pulmonary embolism. Circulation 2000; 102: 211.
106. Missov E, Calzolari C, Davy JM, Leclercq F, Rossi M, Pau B. Cardiac Troponin I in patients with hematologic malignancies. Coron Artery Dis 1997; 8: 537-41.
107. Rifai N, Douglas PS, O'Toole M, Rimm E, Ginsburg GS. Cardiac troponin T and I, electrocardiographic wall motion analyses, and ejection fractions in athletes partecipating in the Hawaii Ironmano Triathlon. Am J Cardiol 1999; 83: 1085-89.
108. Arlati S, Brenna S, Prencipe L, Marocchi A, Casella GP, Lanzani M, et al. Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospective study. Intensive Care Med 2000; 26: 31-7.
109. GUSTO Investigators. An international randomized trial comparing four throbolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
110. PURSUIT Trial Investigators. Inhibition of platelet glycoiprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes: platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 1998; 339: 436-443.
111. Carson JL, Duff A, Poses RM, Berlin JA, Spence RK, Trout R, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 1996; 348: 1055-60.
112. Hebert PC, Wells G, Tweeddale M, Martin C, Marshall J, Pham B, et al. Does transfusion practice affect mortality in critically ill patients? Am J Respir Crit Care Med 1997; 155: 1618-23.
113. Hebert PC, Wells G, Marshall J, Martin C, Tweeddale M, Pagliarello G, et al. Transfusion requirements in critical care: a pilot study. Canadian Critical Care Trials Groups. JAMA 1995; 273: 1439-1444.
114. [Published erratum in JAMA 1995; 274: 944].
115. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators. Canadian Critical Care Trials Group. N Engl J Med 1999; 340: 409-417.
116. Hebert PC, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall J, et al; Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trials Group. Is a low transfusion threshold safe in critically ill patients with cardiovascular disease? Crit Care Med 2001; 29: 227-234.
117. Bracey AW, Radovancevic R, Riggs SA, Houston S, Cozart H, Vaughn WK, et al. Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. Transfusion 1999; 39: 1070-1077.
118. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 1555-1562.
119. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37: 1775-80.
120. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112: 999-1007.
121. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001; 98: 4044-9.
122. Chattopadhyay A, Choudhury TD, Bandyopadhyay D, Datta AG. Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Bipochem Pharmacol 2000; 59: 419-25.
123. Rao SV, Stamler JS. Erythropoietin, anemia, and orthostatic hypotension: the evidence mounts. Clin Auton Res 2002; 12: 141-143.
124. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.